[Determining The Risk of Cardio- and Vasotoxicity of Antitumor Therapy: to Whom, When, Why?]

IF 0.5 4区医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Kardiologiya Pub Date : 2025-02-05 DOI:10.18087/cardio.2025.1.n2717

Yu A Vasyuk, S A Muslov, D A Vyzhigin, E Yu Shupenina, E O Novosel

{"title":"[Determining The Risk of Cardio- and Vasotoxicity of Antitumor Therapy: to Whom, When, Why?]","authors":"Yu A Vasyuk, S A Muslov, D A Vyzhigin, E Yu Shupenina, E O Novosel","doi":"10.18087/cardio.2025.1.n2717","DOIUrl":null,"url":null,"abstract":"<p><p>It is known that the advances in cancer treatment leading to increased survival in malignant neoplasms, entail a variety of adverse cardiovascular toxic effects that can be quite serious and even potentially fatal. An important component that influences the degree of cardiotoxicity risk is the patient's clinical and functional state and the cardiovascular history at the time of cancer diagnosis. This information can be used in practice for the cardiovascular screening and clinical and functional evaluation of a patient with a neoplasm before the start of antitumor therapy. After completion of the cardiotoxic therapy, as well as during subsequent follow-up, it is advisable to re-evaluate the risk of long-term cardiotoxicity to determine the frequency and intensity of cardiovascular monitoring. For convenience of calculating the risk of cardiotoxicity in cancer patients undergoing the antitumor treatment, the authors of this article have developed two computer programs that can be used as PC applications (https://disk.yandex.ru/d/NuhzYnicWo9FSw) and on mobile devices (https://disk.yandex.ru/d/uXAriKZ6qhkULA.). These programs facilitate the selection of the correct strategy for the management of cancer patients that is aimed at reducing the likelihood of cardiotoxic complications of the antitumor treatment.</p>","PeriodicalId":54750,"journal":{"name":"Kardiologiya","volume":"65 1","pages":"3-10"},"PeriodicalIF":0.5000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kardiologiya","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18087/cardio.2025.1.n2717","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

It is known that the advances in cancer treatment leading to increased survival in malignant neoplasms, entail a variety of adverse cardiovascular toxic effects that can be quite serious and even potentially fatal. An important component that influences the degree of cardiotoxicity risk is the patient's clinical and functional state and the cardiovascular history at the time of cancer diagnosis. This information can be used in practice for the cardiovascular screening and clinical and functional evaluation of a patient with a neoplasm before the start of antitumor therapy. After completion of the cardiotoxic therapy, as well as during subsequent follow-up, it is advisable to re-evaluate the risk of long-term cardiotoxicity to determine the frequency and intensity of cardiovascular monitoring. For convenience of calculating the risk of cardiotoxicity in cancer patients undergoing the antitumor treatment, the authors of this article have developed two computer programs that can be used as PC applications (https://disk.yandex.ru/d/NuhzYnicWo9FSw) and on mobile devices (https://disk.yandex.ru/d/uXAriKZ6qhkULA.). These programs facilitate the selection of the correct strategy for the management of cancer patients that is aimed at reducing the likelihood of cardiotoxic complications of the antitumor treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Kardiologiya 医学-心血管系统

CiteScore

1.70

自引率

20.00%

发文量

审稿时长

3-8 weeks

期刊介绍： “Kardiologiya” (Cardiology) is a monthly scientific, peer-reviewed journal committed to both basic cardiovascular medicine and practical aspects of cardiology. As the leader in its field, “Kardiologiya” provides original coverage of recent progress in cardiovascular medicine. We publish state-of-the-art articles integrating clinical and research activities in the fields of basic cardiovascular science and clinical cardiology, with a focus on emerging issues in cardiovascular disease. Our target audience spans a diversity of health care professionals and medical researchers working in cardiovascular medicine and related fields. The principal language of the Journal is Russian, an additional language – English (title, authors’ information, abstract, keywords). “Kardiologiya” is a peer-reviewed scientific journal. All articles are reviewed by scientists, who gained high international prestige in cardiovascular science and clinical cardiology. The Journal is currently cited and indexed in major Abstracting & Indexing databases: Web of Science, Medline and Scopus. The Journal''s primary objectives Contribute to raising the professional level of medical researchers, physicians and academic teachers. Present the results of current research and clinical observations, explore the effectiveness of drug and non-drug treatments of heart disease, inform about new diagnostic techniques; discuss current trends and new advancements in clinical cardiology, contribute to continuing medical education, inform readers about results of Russian and international scientific forums; Further improve the general quality of reviewing and editing of manuscripts submitted for publication; Provide the widest possible dissemination of the published articles, among the global scientific community; Extend distribution and indexing of scientific publications in major Abstracting & Indexing databases.